Bernhard Brehmer1,2, Caroline Kauffmann3, Christian Blank4, Axel Heidenreich3, Axel Bex5. 1. Department of Urology, Diakonie Hospital, Schwaebisch Hall, Germany. bernhard.brehmer@rwth-aachen.de. 2. Department of Urology, University Hospital, Rheinisch-Westfälische Technical University, Aachen, Germany. bernhard.brehmer@rwth-aachen.de. 3. Department of Urology, University Hospital, Cologne, Germany. 4. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 5. Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
PURPOSE: To analyse probability of complete local control and outcome in patients with metastases and local recurrences who have a high probability of failure of local therapy and who were treated with presurgical targeted therapy with the intention to reconsider complete resection or other local therapies such as radiotherapy or ablation. METHOD: From two institutional databases, patients with metastatic or locally recurrent RCC were retrospectively identified who received targeted therapy based on a multidisciplinary tumour board decision because of high probability of failure of local control. RESULTS: From January 2007 until November 2014, 34 patients were treated and included in the analysis. Five patients underwent no local therapy due to insufficient downsizing to attempt resection. The probability of proceeding to local therapy was 85.3 %. Median overall survival of 29 patients with local therapy after pretreatment was 67 months (range 9-173, 95 % CI 90.87) with a median disease-free survival of 12 months (range 0-147 months). The probability to achieve complete local therapy and discontinue targeted therapy was 73.5 % (25 of 34 patients). Median time without systemic therapy was 12 months. CONCLUSION: In a retrospective series of patients with a high probability of failure of local therapy, neoadjuvant targeted therapy was associated with successful complete local treatment in approximately 70 % of patients with a time off targeted therapy of ≥1 year in 50 %. Only number of metastatic sites and the disease-free interval after treatment were associated with outcome.
PURPOSE: To analyse probability of complete local control and outcome in patients with metastases and local recurrences who have a high probability of failure of local therapy and who were treated with presurgical targeted therapy with the intention to reconsider complete resection or other local therapies such as radiotherapy or ablation. METHOD: From two institutional databases, patients with metastatic or locally recurrent RCC were retrospectively identified who received targeted therapy based on a multidisciplinary tumour board decision because of high probability of failure of local control. RESULTS: From January 2007 until November 2014, 34 patients were treated and included in the analysis. Five patients underwent no local therapy due to insufficient downsizing to attempt resection. The probability of proceeding to local therapy was 85.3 %. Median overall survival of 29 patients with local therapy after pretreatment was 67 months (range 9-173, 95 % CI 90.87) with a median disease-free survival of 12 months (range 0-147 months). The probability to achieve complete local therapy and discontinue targeted therapy was 73.5 % (25 of 34 patients). Median time without systemic therapy was 12 months. CONCLUSION: In a retrospective series of patients with a high probability of failure of local therapy, neoadjuvant targeted therapy was associated with successful complete local treatment in approximately 70 % of patients with a time off targeted therapy of ≥1 year in 50 %. Only number of metastatic sites and the disease-free interval after treatment were associated with outcome.
Authors: Thomas Powles; Christian Blank; Simon Chowdhury; Simon Horenblas; John Peters; Jonathan Shamash; Naveed Sarwar; Ekaterini Boleti; Anju Sahdev; Tim O'Brien; Dan Berney; Luis Beltran; Paul Nathan; John Haanen; Axel Bex Journal: Eur Urol Date: 2011-05-17 Impact factor: 20.096
Authors: Saeed Dabestani; Lorenzo Marconi; Fabian Hofmann; Fiona Stewart; Thomas B L Lam; Steven E Canfield; Michael Staehler; Thomas Powles; Börje Ljungberg; Axel Bex Journal: Lancet Oncol Date: 2014-10-26 Impact factor: 41.316
Authors: Jose A Karam; Brian I Rini; Leticia Varella; Jorge A Garcia; Robert Dreicer; Toni K Choueiri; Eric Jonasch; Surena F Matin; Steven C Campbell; Christopher G Wood; Nizar M Tannir Journal: J Urol Date: 2010-12-17 Impact factor: 7.450
Authors: E Jason Abel; Stephen H Culp; Nizar M Tannir; Pheroze Tamboli; Surena F Matin; Christopher G Wood Journal: Eur Urol Date: 2011-07-14 Impact factor: 20.096
Authors: E Jason Abel; Stephen H Culp; Nizar M Tannir; Surena F Matin; Pheroze Tamboli; Eric Jonasch; Christopher G Wood Journal: Eur Urol Date: 2010-10-16 Impact factor: 20.096
Authors: Phillip M Pierorazio; James M McKiernan; Tara R McCann; Supriya Mohile; Daniel Petrylak; Mitchell C Benson Journal: BJU Int Date: 2007-10 Impact factor: 5.588
Authors: Eric Jonasch; Christopher G Wood; Surena F Matin; Shi-Ming Tu; Lance C Pagliaro; Paul G Corn; Ana Aparicio; Pheroze Tamboli; Randall E Millikan; Xuemei Wang; John C Araujo; Wadih Arap; Nizar Tannir Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544